Big pharma firm settles HIV drug disputes with generic makers

Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Gilead loses bid to quash parallel antitrust HIV lawsuit

31 March 2022 Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.

Americas

Gilead sues alleged counterfeit ring over US-wide fake HIV meds plot

20 January 2022 Gilead Sciences has sued an array of pharmaceutical suppliers and distributors accusing them of forming a counterfeiting network and allegedly selling fake versions of its HIV medications.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Big pharma firm settles HIV drug disputes with generic makers

More on this story

Editor's picks

Editor's picks

More features